Southpoint Capital Advisors LP's Form 4 filing
Fennec Pharmaceuticals Inc. (FENC) · filed Nov 20, 2025
- Accession no.
- 0001012975-25-000806
- Filed
- Nov 20, 2025, 4:07 PM ET
- Trade date
- Nov 18, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $170.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Southpoint Capital Advisors LPCIK 0001319998 | 10% Owner |
| Southpoint GP, LPCIK 0001378376 | 10% Owner |
| Southpoint Capital Advisors LLCCIK 0001378377 | 10% Owner |
| Southpoint GP, LLCCIK 0001378378 | 10% Owner |
| Clark John Smith IICIK 0001378379 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 18, 2025 | Common Stock | SSaleDisposed | −19,341 | $8.79F2 | −$170,048.01 | 3,744,741 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The transaction was executed in multiple trades at prices ranging from $8.75 to $8.845. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
Referenced by the price of 1 transaction in Table I.